期刊
CLINICS IN LABORATORY MEDICINE
卷 29, 期 1, 页码 87-+出版社
W B SAUNDERS CO-ELSEVIER INC
DOI: 10.1016/j.cll.2009.01.005
关键词
Proteomics; Biomarkers; Cardiac markers; Multiplex assays; Discovery; Validation; Translational research
资金
- National Heart Lung Blood Institute Proteomic Initiative [N01-HV-28,120]
- SCCOR program (Specialized Centers of Clinically Oriented Research) [1 P50 HL 084,946-01]
- Clinical Translational Science [1U54RR023561-01A1]
- Daniel P. Amos Foundation
- Novartis Research Foundation
- Swiss National Science Foundation [PBSKP3-124604]
- Swiss National Science Foundation (SNF) [PBSKP3-124604] Funding Source: Swiss National Science Foundation (SNF)
Proteomics is fulfilling its potential and beginning to impact the diagnosis and therapy of cardiovascular disease. As de novo proteomics analysis gets more streamlined, and robust high-throughput methods are developed, more and more attention is being directed toward the field of cardiovascular serum and plasma biomarker discovery. To take cardiovascular proteomics from bench to bedside, great care must be taken to achieve reproducible results. Despite technical advances, however, the absolute number of clinical biomarkers thus far discovered by a proteomics approach is small. Although several factors contribute to this lack, one step is to build translation teams involving a close collaboration between researchers and clinicians.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据